RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Hypoxia-inducible factors (HIFs), ETS-1, MYC, and β-catenin act as master regulators that constitutively activate oncogenic ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

“Newer RNA interference therapeutics, patisiran and vutrisiran, show significant promise as an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM),” Farhan Naeem, MD, from ...

A recent eGastroenterology review by Professor Intissar Anan highlights major breakthroughs in transthyretin amyloidosis ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease. The ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ damage.

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in ...